Welcome to our dedicated page for Crescent Biopharma SEC filings (Ticker: CBIO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Crescent Biopharma filings document a clinical-stage oncology biotechnology issuer with ordinary shares listed on Nasdaq. The company’s Form 8-K reports furnish quarterly and annual financial results, business highlights, and pipeline updates involving CR-001, ADC programs, and collaboration activity.
Its SEC record also includes a definitive proxy statement covering governance, executive compensation, equity awards, shareholder voting matters, and board-related disclosures. Registration statement materials describe the company’s business, capitalization, preferred stock, warrants, convertible instruments, risk factors, and public-company structure.
CRESCENT BIOPHARMA, INC. director Jonathan Violin received a grant of stock options covering 11,050 ordinary shares. The options carry an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.
CRESCENT BIOPHARMA, INC. director David Charles Lubner received a grant of stock options covering 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service.
CRESCENT BIOPHARMA, INC. director Alexandra Balcom received a grant of stock options covering 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036.
The grant vests in full on the earlier of June 2, 2027 or the date of the company’s next annual meeting of shareholders, as long as she continues serving the company. Following this grant, she holds options on 11,050 shares directly, reflecting routine equity-based compensation rather than an open-market purchase or sale.
CRESCENT BIOPHARMA, INC. director Susan Moran received a grant of options to buy 11,050 ordinary shares. The options have an exercise price of $17.01 per share and expire on June 2, 2036. They vest in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to her continued service, leaving her with 11,050 derivative securities directly held after this transaction.
CRESCENT BIOPHARMA, INC. reported an insider equity award involving investment entities affiliated with Fairmount Funds. A stock option for 11,050 ordinary shares was granted at an exercise price of $17.0100 per share, expiring on June 2, 2036.
The option was awarded to Peter Harwin, who holds it for one or more investment vehicles managed by Fairmount Funds Management LLC. It vests in full on the earlier of June 2, 2027 or the company’s next annual shareholder meeting, subject to his continued service. Fairmount, Harwin, and Tomas Kiselak state they disclaim beneficial ownership beyond any pecuniary interest.
Crescent Biopharma, Inc. reported the results of its annual general meeting of shareholders held on June 2, 2026. Shareholders elected Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE as Class II directors to serve until the 2029 annual general meeting.
Investors also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on a non-binding basis the compensation of named executive officers. Shareholders recommended holding future advisory votes on executive pay every year, and the Board agreed to follow an annual frequency.
Crescent Biopharma, Inc. (CBIO) disclosure: Tang Capital Management, LLC and related persons report beneficial ownership of 1,160,000 Ordinary Shares, representing 4.21% of the class. The percentage is calculated from 27,571,935 Ordinary Shares outstanding as of April 7, 2026, cited from a DEF 14A filed April 21, 2026.
The filing lists shared voting and dispositive power over these shares among Tang Capital Management, LLC, Tang Capital Partners, LP, Tang Capital Partners International, LP, Tang Capital Partners III, Inc. and Kevin Tang. The statement is signed by Kevin Tang on 05/15/2026.
Crescent Biopharma reports a Schedule 13G filing showing Balyasny entities and Dmitry Balyasny beneficially own 1,510,033 shares of Common Stock. The filing states this represents approximately 5.48% of class A common stock based on 27,556,767 shares outstanding as of February 23, 2026. The disclosed position arises from BAM’s investment‑manager relationships with Atlas Private Holdings (Cayman) Ltd. (670,000 shares) and Atlas Diversified Master Fund, Ltd. (840,033 shares); voting and dispositive power is reported as sole for the 1,510,033 shares.
Crescent Biopharma, Inc. files a prospectus supplement updating its resale registration for 19,580,843 ordinary shares to permit resale or other dispositions by the identified selling securityholders. The resale amount consists of a mix of outstanding shares, pre-funded warrant shares and shares issuable on conversion of Series A preferred.
Shares outstanding were 27,571,935 as of April 24, 2026. The supplement incorporates information from Crescent’s Form 10-Q for the quarter ended March 31, 2026.
Crescent Biopharma reported first quarter 2026 results alongside a detailed oncology pipeline update. The company is running its global Phase 1/2 ASCEND trial of CR-001, a PD-1 x VEGF bispecific antibody, across multiple solid tumors and preparing ADC combination trials beginning in the second half of 2026.
CR-002, a PD-L1–targeted ADC, is planned to enter the clinic in the second half of 2026, while CR-003, an ITGB6-targeted ADC, is already in a Phase 1/2 study in China. Multiple proof-of-concept data readouts are anticipated starting in early 2027.
Financially, Crescent ended March 31, 2026 with cash and cash equivalents of $189.2 million, which management expects will fund operations into 2028. Q1 2026 revenue was $1.0 million, research and development expense was $17.9 million, general and administrative expense was $7.9 million, and net loss was $23.3 million, or $0.70 per basic and diluted share.